Varex Imaging Corporation · NASDAQ:VREX

Varex Imaging — Q2 2021 Earnings Presentation

22 slides from Varex Imaging's earnings presentation, May 4, 2021

  1. Slide 1: Q2 FY21 Earnings Presentation

    Slide 1: Q2 FY21 Earnings Presentation

    Solutions in Sight™ Q2 FY21 Earnings Presentation May 4, 2021 Proprietary and Confidential Information

  2. Slide 2: Forward Looking Statements / Non-GAAP Measures

    Slide 2: Forward Looking Statements / Non-GAAP Measures

    Forward Looking Statements / Non-GAAP Measures Forward Looking Statements Certain statements in this supplement contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward looking statements incl

  3. Slide 3: Q2 FY21 Results

    Slide 3: Q2 FY21 Results

    Q2 FY21 Results Non-GAAP Non-GAAP Revenue Cash Gross Margin* EPS* $204M $111M 35% $0.35  Revenues exceeded pre-COVID levels  Future growth expected from: • China CT expansion • Additional elective procedure volumes • Expansion of Industrial activity  Gross Margin increased sequentially  Signific

  4. Slide 4: Q2 FY21 Sequential Trends

    Slide 4: Q2 FY21 Sequential Trends

    Q2 FY21 Sequential Trends CT Mammography Radiography & Fluoroscopy Others Oncology Industrial Dental 4

  5. Slide 5: Quarterly Highlight: X-Ray Tubes

    Slide 5: Quarterly Highlight: X-Ray Tubes

    Quarterly Highlight: X-Ray Tubes CT Growth in China  Initial roll-out for first few years of 16 slice CT systems  Increased interest in 64 & 128 slice CT systems  CT tubes for service replacement & new CT systems Growth in Medical X-Ray Tubes  Strong gains in mammography  Other elective procedu

  6. Slide 6: Conventional vs Nanotube Emitter

    Slide 6: Conventional vs Nanotube Emitter

    Conventional vs Nanotube Emitter Conventional Emitter Nanotube Emitter • Heated tungsten filament releases electrons • Electric field extracts electrons • Operating Temperature: 2400 C • Operating Temperature: 25 C • Filament needs power • Nanotube emitter does not need power • Low packing density f

  7. Slide 7: Nanotube Based Multi-Emitter X-Ray Sources

    Slide 7: Nanotube Based Multi-Emitter X-Ray Sources

    Nanotube Based Multi-Emitter X-Ray Sources Next Generation ”Static” Imaging Applications Potential Benefits Lower Total Cost of Ownership • Reduces mechanical complexity and costs • Lower maintenance costs Imaging Performance • Can eliminate motion artifacts • Dual Energy imaging Multi-Emitter “soli

  8. Slide 8: Status Of Nanotube Sources Development

    Slide 8: Status Of Nanotube Sources Development

    Status Of Nanotube Sources Development Application Areas Targeted Energy Spectrum: 40kV to 180kV • Full Body CT Accelerated • Head CT Life Testing: 1 Billion Projections / Emitter • Breast Tomosynthesis  Designs and Simulations • C-arms / O-arms  Prototypes for Testing Emissions and Focal • DR Tom

  9. Slide 9: Q2 FY21 Revenue Details

    Slide 9: Q2 FY21 Revenue Details

    Q2 FY21 Revenue Details Segment Mix Geographic Mix ($ in millions) ($ in millions) $47 $65 $71 $157 $68 Medical Industrial Americas EMEA APAC Revenue, $M Q2 21 Q1 21 Q4 20 Q3 20 Q2 20 Revenue, $M Q2 21 Q1 21 Q4 20 Q3 20 Q2 20 Medical 157 139 136 138 155 Americas 71 62 64 59 63 Industrial 47 38 34 34

  10. Slide 10: Quarterly Results - GAAP

    Slide 10: Quarterly Results - GAAP

    Quarterly Results - GAAP $ in Millions, except per share data Q2 FY21 Q1 FY21 Q2 FY20 Revenue $204 $177 $197 Gross Margin 32% 32% 29% $49 $51 $56 Operating Expenses 24% 29% 29% $16 $6 $1 Operating Income 8% 3% 1% Net Earnings $3 $(6) $(2) EPS $0.08 $(0.16) $(0.05) 10 Proprietary and Confidential Inf

  11. Slide 11: Quarterly Results - Non-GAAP

    Slide 11: Quarterly Results - Non-GAAP

    Quarterly Results - Non-GAAP* $ in Millions, except per share data Q2 FY21 Q1 FY21 Q2 FY20 Revenue $204 $177 $197 Gross Margin (Non-GAAP) 35% 34% 32% $45 $46 $52 Operating Expenses (Non-GAAP) 22% 26% 27% $26 $14 $11 Operating Income (Non-GAAP) 13% 8% 5% Net Earnings (Non-GAAP) $14 $3 $5 EPS (Non-GAA

  12. Slide 12: Select Balance Sheet Data

    Slide 12: Select Balance Sheet Data

    Select Balance Sheet Data $ in Millions Q2 FY21 Q1 FY21 Q2 FY20 Assets Cash and Cash Equivalents $111 $106 $24 Accounts Receivable, net $129 $121 $127 Inventories $248 $270 $282 Total Assets $1,133 $1,137 $1,082 Liabilities Accounts Payable $52 $68 $79 Long-Term Debt, net $461 $460 $383 Total Liabil

  13. Slide 13: Select Debt and Cash Flow Data

    Slide 13: Select Debt and Cash Flow Data

    Select Debt and Cash Flow Data $ in Millions Q2 FY21 Q1 FY21 Q2 FY20 Debt Gross Debt $512 $514 $388 (Ratings: Moody’s B2 / S&P B) Net Debt1 $401 $408 $364 Adjusted EBITDA2 Adjusted EBITDA $33 $22 $19 Cash Performance Cash Flow from Operations $13 $7 $1 Capital Expenditures $3 $4 $6 Cash Interest $0

  14. Slide 14: Outlook Q3 FY21

    Slide 14: Outlook Q3 FY21

    Outlook Q3 FY21 Guidance Non-GAAP Revenues, $M $195 - $215 EPS Per Diluted Share $0.15 - $0.35 Assumptions Non-GAAP Gross Margin 33% - 35% Operating Expenses, $M $44 - $45 14

  15. Slide 15: Q&A

    Slide 15: Q&A

    Solutions in Sight™ Q&A Proprietary and Confidential Information

  16. Slide 16: Non-GAAP Reconciliation

    Slide 16: Non-GAAP Reconciliation

    Solutions in Sight™ Non-GAAP Reconciliation Proprietary and Confidential Information

  17. Slide 17: Reconciliation Between GAAP and Non-GAAP Financial Measures (Unaudited)

    Slide 17: Reconciliation Between GAAP and Non-GAAP Financial Measures (Unaudited)

    Reconciliation Between GAAP and Non–GAAP Financial Measures (Unaudited) Three Months Ended Six Months Ended (In millions, except per share amounts) April 2, 2021 April 3, 2020 April 2, 2021 April 3, 2020 GROSS PROFIT RECONCILIATION Revenues $ 203.5 $ 197.0 $ 380.6 $ 397.1 Gross profit $ 64.6 $ 57.6

  18. Slide 18: Reconciliation Between GAAP and Non-GAAP Financial Measures (Unaudited)

    Slide 18: Reconciliation Between GAAP and Non-GAAP Financial Measures (Unaudited)

    Reconciliation Between GAAP and Non–GAAP Financial Measures (Unaudited) Three Months Ended Six Months Ended (In millions, except per share amounts) April 2, 2021 April 3, 2020 April 2, 2021 April 3, 2020 OPERATING INCOME RECONCILIATION Operating income $ 15.8 $ 1.4 $ 21.9 $ 6.0 Amortization of intan

  19. Slide 19: Reconciliation Between GAAP and Non-GAAP Financial Measures (Unaudited)

    Slide 19: Reconciliation Between GAAP and Non-GAAP Financial Measures (Unaudited)

    Reconciliation Between GAAP and Non–GAAP Financial Measures (Unaudited) Three Months Ended Six Months Ended (In millions, except per share amounts) April 2, 2021 April 3, 2020 April 2, 2021 April 3, 2020 INCOME (LOSS) BEFORE TAXES RECONCILIATION Income (loss) before taxes $ 3.2 $ (1.1) $ (1.5) $ (2.

  20. Slide 20: Reconciliation Between GAAP and Non-GAAP Financial Measures (Unaudited)

    Slide 20: Reconciliation Between GAAP and Non-GAAP Financial Measures (Unaudited)

    Reconciliation Between GAAP and Non–GAAP Financial Measures (Unaudited) Three Months Ended Six Months Ended (In millions, except per share amounts) April 2, 2021 April 3, 2020 April 2, 2021 April 3, 2020 ADJUSTED EBITDA RECONCILIATION Net income (loss) attributable to Varex $ 3.1 $ (1.9) $ (3.3) $ (

  21. Slide 21: Discussion of Non-GAAP Financial Measures

    Slide 21: Discussion of Non-GAAP Financial Measures

    Discussion of Non-GAAP Financial Measures This presentation includes non-GAAP financial measures derived from our Condensed Consolidated Statements of Earnings. These measures are not presented in accordance with, nor are they a substitute for U.S. generally accepted accounting principles, or GAAP.

  22. Slide 22: Solutions in Sight™

    Slide 22: Solutions in Sight™

    \ if VAREX \ Solutions in Sight™

Source: Internet Archive copy of vareximaging.com

More decks from Varex Imaging Corporation

All 25 Varex Imaging decks